Moberg Pharma to participate at EADV and CPHI
STOCKHOLM, September 28, 2026. Moberg Pharma AB (OMX: MOB) will participate at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, September 30–October 3, and the Convention on Pharmaceutical Ingredients (CPHI) in Milan, October 6–8, 2026. The events provide important opportunities to engage with leading dermatology experts, commercial partners and pharmaceutical manufacturers ahead of the broader international rollout of MOB-015.
MOB-015 is a topical terbinafine treatment for onychomycosis. The product is currently approved in 14 countries and is marketed as